Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 4/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31619577 | 1.00 | ALDH1A1 (0.55) | ALDH1A1KDM4EACHEMETAP1HTR2A | |
| SCHEMBL31650179 | 0.87 | ACHE (0.64) | ALDH1A1KDM4EACHEMETAP1HTR2A | |
| SCHEMBL29194896 | 0.82 | METAP1 (0.50) | ALDH1A1KDM4EACHEMETAP1HTR2A | |
| SCHEMBL3170281 | 0.80 | METAP1 (0.48) | ALDH1A1KDM4EACHEMETAP1HTR2A | |
| SCHEMBL9523559 | 0.78 | MAOB (0.56) | ALDH1A1KDM4EMETAP1HTR2AHTR2C | |
| SCHEMBL344572 | 0.78 | CYP19A1 (0.50) | ALDH1A1KDM4EMETAP1HTR2AHTR2C | |
| SCHEMBL344573 | 0.78 | CYP19A1 (0.50) | ALDH1A1KDM4EMETAP1HTR2AHTR2C | |
| SCHEMBL16233623 | 0.78 | DRD2 (0.56) | ACHEHTR2AHTR2CHTR2BCYP19A1 | |
| SCHEMBL14279806 | 0.78 | DRD2 (0.56) | ACHEHTR2AHTR2CHTR2BCYP19A1 | |
| SCHEMBL13799409 | 0.78 | DRD2 (0.56) | ACHEHTR2AHTR2CHTR2BCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-12459890-B2 | Salt and crystal form of compound having agonistic activity to S1P5 receptor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-10-03 | — | — | US | disclosed |
| EP-4431157-A2 | 1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | ONO Pharmaceutical Co., Ltd. (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-30 | — | — | US | disclosed |
| EP-4019496-B1 | SALT AND CRYSTAL FORM OF COMPOUND HAVING AGONISTIC ACTIVITY TO S1P5 RECEPTOR | ONO PHARMACEUTICAL CO (JP) | 2024-06-05 | — | — | EP | disclosed |
| CN-111757869-B | Compounds having S1P5 receptor agonistic activity | 小野药品工业株式会社 | 2024-03-08 | — | — | CN | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11471436-B2 | Dihydronaphthalene derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-10-18 | — | — | US | disclosed |
| US-20070276000-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-11-29 | — | — | US | disclosed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| EP-0325963-B1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES AND -INDANES | ABBOTT LABORATORIES (US) | 1993-09-22 | — | — | EP | disclosed |
| US-5140040-A | Alpha-2-adrenergic receptor antagonist; glaucoma; congestive heart failure; hypotensive agents; headaches; metabolic disorders (diabetes, obesity) | ABBOTT LABORATORIES (US) | 1992-08-18 | — | — | US | disclosed |
| US-5128362-A | Antidepressant, antiglaucoma | ABBOTT LABORATORIES (US) | 1992-07-07 | — | — | US | disclosed |
| US-5086074-A | Selective adrenergic receptor antagonists | ABBOTT LABORATORIES (US) | 1992-02-04 | — | — | US | disclosed |
| EP-0395734-A4 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | — | 1991-01-02 | — | — | EP | disclosed |
| EP-0395734-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1990-11-07 | — | — | EP | disclosed |
| EP-0325963-A1 | 1-Aminomethyl-1,2,3,4-tetrahydronaphthalenes and -indanes | ABBOTT LABORATORIES (US) | 1989-08-02 | — | — | EP | disclosed |
| WO-1989006645-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1989-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459890-B2 | Salt and crystal form of compound having agonistic activity to S1P5 receptor | S1PR5, S1PR1, S1PR3 | ALDH1A1 3449/4885KDM4E 3725/4885ACHE 4168/4885 |
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | ALDH1A1 2382/4885KDM4E 2814/4885ACHE 2048/4885 |
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | ALDH1A1 2382/4885KDM4E 2814/4885ACHE 2048/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | ALDH1A1 1679/4885KDM4E 1936/4885ACHE 3475/4885 |
| US-11471436-B2 | Dihydronaphthalene derivative | S1PR5, LPAR5, S1PR1 | ALDH1A1 1215/4885KDM4E 2998/4885ACHE 3625/4885 |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | ALDH1A1 4449/4885KDM4E 2167/4885ACHE 3673/4885 |
| US-20070276000-A1 | CHEMICAL COMPOUNDS | GPER1, ESR2, ESR1 | ALDH1A1 586/4885KDM4E 1631/4885ACHE 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.